The effect of glucagon‐like peptide‐1 receptor agonists on serum uric acid concentration: A systematic review and meta‐analysis
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Aims: Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are a class of medications mainly used for the treatment of type 2 diabetes. They improve glucose tolerance, increase insulin secretion and induce weight loss. There is controversy about the effect of GLP‐1 RAs on serum uric acid (SUA) concentration. Our systematic review aims to objectively answer whether GLP‐1 RAs affect SUA levels. Methods: We performed a systematic search on PubMed, Web of Science, Embase, Scopus and Google Scholar datasets up to 27August 2021 with a language restriction of English only. Randomized controlled trials, observational studies, uncontrolled trials and conference abstracts were included. Studies with insufficient data, irrelevant types of study and follow‐up duration of less than a month were excluded from the review. After critical appraisal by the Joanna Briggs Institute checklists, articles underwent data extraction using a prespecified Microsoft Excel sheet. Results: Of 1004 identified studies, 17 were eligible for inclusion in this systematic review. Pre‐ to post‐administration analysis of GLP‐1 RA effects on SUA demonstrated that GLP‐1 RAs could significantly reduce SUA concentration (difference in means −0.341, SE 0.063, P value <0.001). However, when compared to placebo, GLP‐1RAs did not perform any better in lowering SUA concentration (difference in means −0.455, SE 0.259, P value 0.079). Surprisingly, the active controls, which included insulin, metformin, sodium‐glucose co‐transporter 2 (SGLT‐2) inhibitors and dipeptidyl‐peptidase 4 inhibitors, did outperform GLP‐1 RAs in reducing SUA concentration (difference in means 0.250, SE 0.038, P value <0.001). Conclusions: Administration of GLP‐1 RAs can result in a significant reduction in SUA concentration. However, this reduction is less than that seen with the use of insulin, metformin and SGLT‐2 inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Page, M. J., Moher, D., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n160 · Cited by 13,262
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Kristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30249-9 · Cited by 1,663
Liraglutide and renal outcomes in type 2 diabetes
Mann, J. F. E., Ørsted, D. D., Brown-Frandsen, K., Marso, S. P., Poulter, N. R., Rasmussen, S., Tornøe, K., Zinman, B., & Buse, J. B. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1616011 · Cited by 1,253
The Cardiovascular Biology of Glucagon-like Peptide-1
Drucker, D. J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.06.009 · Cited by 665
Zhao, Y., Xu, L., Tian, D., Xia, P., Zheng, H., Wang, L., & Chen, L. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13101 · Cited by 333 · cited 1×
“Recent reports indicate that SGLT2 inhibitors can cause a significant reduction in SUA concentration through a mechanism similar to that of antihyperuricemia drugs.(40) These agents increase uric acid excretion by suppressing the activity of GLUT9b, a major regulator of uric acid homeostasis at the level of the proxim…”
BackgroundGLP-1 receptor agonists: an updated review of head-to-head clinical studies
Trujillo, J. M., Nuffer, W., & Smith, B. A. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018821997320 · Cited by 289
Dutour, A., Abdesselam, I., Ancel, P., Kober, F., Mrad, G., Darmon, P., Ronsin, O., Pradel, V., Lesavre, N., Martin, J. C., et al. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12680 · Cited by 262 · cited 1×
“twice-daily exenatide on SUA concentration in patients with metabolic syndrome and T2DM, and reported no significant alterations.(32,52) In addition, in a post hoc analysis by Muskiet et al, twicedaily exenatide did not cause a significant change in SUA levels compared to insulin glargine.”
MethodKuchay, M. S., Krishan, S., Mishra, S. K., Choudhary, N. S., Singh, M. K., Wasir, J. S., Kaur, P., Gill, H. K., Bano, T., Farooqui, K. J., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05265-7 · Cited by 249
GLP-1 receptor agonists and kidney protection
Greco, E., Russo, G., Giandalia, A., Viazzi, F., Pontremoli, R., & De Cosmo, S. (2019) · Medicina · doi:10.3390/medicina55060233 · Cited by 173
Yaribeygi, H., Rashidy-Pour, A., Atkin, S. L., Jamialahmadi, T., & Sahebkar, A. (2021) · Life Sciences · doi:10.1016/j.lfs.2020.118645 · Cited by 96
Self-citationNakashima, S., Matsui, T., Takeuchi, M., & Yamagishi, S.-I. (2014) · Hormone and Metabolic Research · doi:10.1055/s-0034-1371892 · Cited by 90
Rezaei, S., Tabrizi, R., Nowrouzi-Sohrabi, P., Jalali, M., Atkin, S. L., Al-Rasadi, K., Jamialahmadi, T., & Sahebkar, A. (2021) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2021/8936865 · Cited by 65
Self-citationJi, L., Jiang, H., An, P., Deng, H., Liu, M., Li, L., Feng, L., Song, B., Han-Zhang, H., Ma, Q., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101088 · Cited by 63
Tonneijck, L., Muskiet, M. H. A., Smits, M. M., Hoekstra, T., Kramer, M. H. H., Danser, A. H. J., Diamant, M., Joles, J. A., & van Raalte, D. H. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12985 · Cited by 62
Yaribeygi, H., Farrokhi, F. R., Abdalla, M. A., Sathyapalan, T., Banach, M., Jamialahmadi, T., & Sahebkar, A. (2021) · Journal of Diabetes Research · doi:10.1155/2021/6518221 · Cited by 31
Self-citationChou, C., & Chuang, S. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13314 · Cited by 25
Effect of exenatide on fat deposition and a metabolic profile in patients with metabolic syndrome
González-Ortiz, M., Martínez-Abundis, E., Robles-Cervantes, J. A., & Ramos-Zavala, M. G. (2011) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2010.0025 · Cited by 14 · cited 2×
“twice-daily exenatide on SUA concentration in patients with metabolic syndrome and T2DM, and reported no significant alterations.(32,52) In addition, in a post hoc analysis by Muskiet et al, twicedaily exenatide did not cause a significant change in SUA levels compared to insulin glargine.”
MethodResult
Cited by
Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight
Ji, L., Jiang, H., Bi, Y., Li, H., Tian, J., Liu, D., Zhao, Y., Qiu, W., Huang, C., Chen, L., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2411528 · Cited by 125
Ji, L., Gao, L., Jiang, H., Yang, J., Yu, L., Wen, J., Cai, C., Deng, H., Feng, L., Song, B., et al. (2022) · eClinicalMedicine · doi:10.1016/j.eclinm.2022.101691 · Cited by 83
Winther, J. B., & Holst, J. J. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15693 · Cited by 47
Metadata
- Authors
- Najafi, S., Bahrami, M., Butler, A. E., & Sahebkar, A.
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2022-04-17
- Volume
- 88
- Issue
- 8
- Pages
- 3627-3637
- ISSN
- 0306-5251 (ISSN-L)
- 1365-2125
- OpenAlex
- W4224068676
- Cited by
- 39
- References
- 19
- FWCI
- 1.35
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.